As the process of working on a feasibility study for a possible merger or reorganizational process between Clymer, Sherman ...

A new study shows an inverse relationship between screen time when young and academic achievement later, giving parents ...

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

Asked to list stereotypes they had heard about themselves or other Native Americans, more than 200 middle school-age citizens ...

CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) ("CoTec" or the "Company") is pleased to announce Québec-based BBA Inc. ("BBA") ...

Lenvatinib plus pembrolizumab and chemotherapy did not significantly improve overall survival in metastatic ESCC compared to pembrolizumab and chemotherapy alone. Median overall survival was 17.6 ...

The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...

Vizsla Silver stock has upside potential, thanks to a high-grade Panuco project that offers robust mine economics. Read what ...

Early-onset hypertension during atezolizumab plus bevacizumab therapy predicts improved survival in unresectable HCC.

A father is asking for advice on how to encourage his son when the 10-year-old's mother is putting pressure on him to be ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...

Alectinib showed a 22% reduction in death risk compared to crizotinib in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. Significant OS benefits were observed in ...